Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 18/20 | 0.81 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.73 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.73 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.73 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2470746 | 0.89 | PIK3CA (1.00) | PIK3CAPIK3CDPIK3CBPIK3CGROCK2 | |
| SCHEMBL1821760 | 0.87 | PIK3CA (0.84) | PIK3CAPIK3CDPIK3CBPIK3CGROCK2 | |
| SCHEMBL2473407 | 0.86 | PIK3CA (1.00) | PIK3CAPIK3CDPIK3CBPIK3CGROCK2 | |
| SCHEMBL1821956 | 0.85 | PIK3CA (0.80) | PIK3CAPIK3CDPIK3CBPIK3CGROCK2 | |
| SCHEMBL1821106 | 0.85 | PIK3CA (1.00) | PIK3CAPIK3CDPIK3CBPIK3CGROCK2 | |
| SCHEMBL1823772 | 0.85 | PIK3CA (0.81) | PIK3CAPIK3CDPIK3CBPIK3CGROCK2 | |
| SCHEMBL1821854 | 0.85 | PIK3CA (1.00) | PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL2468159 | 0.84 | PIK3CA (0.83) | PIK3CAPIK3CDPIK3CBPIK3CGROCK2 | |
| SCHEMBL14748414 | 0.84 | PIK3CA (0.82) | PIK3CAPIK3CDPIK3CBPIK3CGROCK2 | |
| SCHEMBL1822839 | 0.84 | PIK3CA (0.79) | PIK3CAPIK3CDPIK3CBPIK3CGROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767669-B2 | Small molecule PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-08-03 | — | — | US | disclosed |
| US-20090060912-A1 | SMALL MOLECULE PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | CHIRON CORPORATION (US) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090060912-A1 | SMALL MOLECULE PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | PI4KB, AKT3, PI4KA | PIK3CA 8/4885PIK3CD 11/4885PIK3CB 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.